- Home
- JFU vs SABS Comparison
JFU vs SABS Comparison
Compare JFU & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- SABS
- Stock Information
- Founded
- JFU 2006
- SABS 2014
- Country
- JFU China
- SABS United States
- Employees
- JFU N/A
- SABS N/A
- Industry
- JFU Finance: Consumer Services
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- SABS Health Care
- Exchange
- JFU Nasdaq
- SABS Nasdaq
- Market Cap
- JFU 17.1M
- SABS 15.8M
- IPO Year
- JFU 2019
- SABS N/A
- Fundamental
- Price
- JFU $1.61
- SABS $2.55
- Analyst Decision
- JFU
- SABS Strong Buy
- Analyst Count
- JFU 0
- SABS 5
- Target Price
- JFU N/A
- SABS $11.60
- AVG Volume (30 Days)
- JFU 17.7K
- SABS 4.3M
- Earning Date
- JFU 01-01-0001
- SABS 08-07-2025
- Dividend Yield
- JFU N/A
- SABS N/A
- EPS Growth
- JFU N/A
- SABS N/A
- EPS
- JFU 0.09
- SABS N/A
- Revenue
- JFU $40,614,155.00
- SABS $377,835.00
- Revenue This Year
- JFU N/A
- SABS N/A
- Revenue Next Year
- JFU N/A
- SABS N/A
- P/E Ratio
- JFU $17.27
- SABS N/A
- Revenue Growth
- JFU N/A
- SABS N/A
- 52 Week Low
- JFU $1.01
- SABS $1.00
- 52 Week High
- JFU $3.60
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- JFU 53.53
- SABS 58.13
- Support Level
- JFU $1.60
- SABS $2.25
- Resistance Level
- JFU $1.78
- SABS $2.85
- Average True Range (ATR)
- JFU 0.17
- SABS 0.60
- MACD
- JFU 0.00
- SABS -0.01
- Stochastic Oscillator
- JFU 30.91
- SABS 12.62
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.